Eli Lilly/LLY
$777.90
0.37%-
1D1W1MYTD1YMAX
About Eli Lilly
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.
Ticker
LLY
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology & Drugs
CEO
David Ricks
Employees
43,000
Headquarters
Indianapolis, United States
Website
www.lilly.com
Eli Lilly Metrics
BasicAdvanced
$739B
Market cap
114.48
P/E ratio
$6.79
EPS
0.36
Beta
$4.69
Dividend rate
0.67%
Dividend yield
Price and volume
Market cap
$739B
Beta
0.35788
52-week high
$800.78
52-week low
$419.80
Average daily volume
3M
Dividend rate
$4.69
Financial strength
Current ratio
1.354
Quick ratio
1.026
Long term debt to equity
191.692
Total debt to equity
204.582
Dividend payout ratio (TTM)
71.2%
Interest coverage (TTM)
30.83%
Management effectiveness
Return on assets (TTM)
10.48%
Return on equity (TTM)
51.15%
Return on investment (TTM)
14.92%
Valuation
Price to earnings (TTM)
114.483
Price to revenue (TTM)
20.572
Price to book
57.695
Price to tangible book (TTM)
665.703
Five year average dividend yield
1.14%
Dividend yield (TTM)
0.6%
Forward dividend yield
0.67%
Growth
Revenue change (TTM)
29.76%
Earnings per share change (TTM)
7.85%
3-year revenue growth
11.62%
3-year earnings per share growth
-5.1%
3-year dividend per share growth
15.15%
What the Analysts think about Eli Lilly
Analyst Ratings
Majority rating from 28 analysts.
Price Targets
Average projection from 24 analysts.
High $1,023.00
Low $540.00
$777.90
Current price
$856.61
Average price target
Eli Lilly Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$8.8B
-6.26%
Net income
$2.2B
2.43%
Profit margin
25.58%
9.27%
Eli Lilly Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$2.11
$0.10
$2.49
$2.58
-
Expected
$1.98
-$0.13
$2.22
$2.46
$2.76
Surprise
6.6%
-174.32%
12.22%
4.95%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $739B as of May 09, 2024.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 114.48 as of May 09, 2024.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of May 09, 2024, the dividend rate is $4.69 and the yield is 0.67%. Eli Lilly has a payout ratio of 71.2% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment is scheduled for June 10, 2024.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the Eli Lilly stock price target?
The target price for Eli Lilly (LLY) stock is $856.61, which is 10.68% above the current price of $773.97. This is an average based on projections from 24 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell Eli Lilly stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.